T he risk of atrial fibrillation-associated ischemic stroke can be significantly mitigated by anticoagulant therapy with a proven 67% relative risk reduction in ischemic stroke compared with no antithrombotic use. 1 Despite this significant therapeutic effect, there still exists substantial underuse of anticoagulants. 2 This underuse is driven by exaggerated concerns for anticoagulant-related bleeding complications and in particular, hemorrhagic stroke. 3 This concern is further amplified in patients with cerebral microbleeds (CMBs) on MRI (MRI). Whether patients with atrial fibrillation and CMBs on MRI can be safely anticoagulated is a current topic of debate that was recently highlighted by a "Controversies in Stroke" and an area of uncertainty in a recent statement by the American Heart Association/American Stroke Association. 4, 5 A meta-analysis examining the risk of CMBs for future ischemic and hemorrhagic strokes after an ischemic stroke or transient ischemic attack (TIA) pooled data of 5068 patients across 15 observational studies and revealed that the presence of CMBs was associated with greater relative risk of both ischemic and hemorrhagic strokes during a median followup of 18 months. 6 However, the relative and absolute risks of hemorrhagic stroke increased more steeply with greater CMB counts than the risks of ischemic stroke, magnifying once again questions surrounding optimal antithrombotic therapy in patients with ischemic stroke/TIA with CMBs, and particularly in patients with greater CMB counts (≥5 CMBs), multiple strictly lobar CMBs suggestive of cerebral amyloid angiopathy or mixed CMB topography presumably marking advanced cerebral small vessel disease. 7 In this opinion piece, we apply the risk estimates from this pooled meta-analysis to data reported in recent large, international atrial fibrillation (AF) randomized trials, with the aim of calculating crude estimates on the rates of ischemic and hemorrhagic strokes, as well as margins of benefit, in trial participants stratified by hypothetical CMB status at study entry.
Methods
We extracted reported rates of hemorrhagic and ischemic stroke from subgroups of patients with previous ischemic stroke/TIA from 5 randomized clinical trials assessing stroke prevention in AF published since 2010. [8] [9] [10] [11] [12] When 2 dosages of anticoagulants were reported separately, we chose the higher dosage regimen. For the warfarin comparator, we used data from ROCKET-AF (The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) because its study cohort included the largest sample of prior ischemic stroke/TIA, 11 and for aspirin, we used data from the AVERROES trial (Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment). 8 The risk ratios (RRs) of ischemic and hemorrhagic strokes in patients with CMBs relative to patients without CMBs reported by Wilson and colleagues 6 (highlighted in Table 1 ) were used to estimate absolute rates of these events stratified according to theoretical CMB status among trial participants. We calculated the estimated event rates for the following hypothetical CMB categories (1) any CMB; (2) 1 CMB, 2 to 4 CMBs, or ≥5 CMBs (mutually exclusive); and (3) strictly lobar, strictly deep, or mixed CMBs (mutually exclusive) by multiplying the RR of ischemic and hemorrhagic strokes relative to patients without CMBs reported for these categories by Wilson et al, 6 by the observed ischemic and hemorrhagic stroke event rates reported in each clinical trial (Table 1) .
We then estimated the absolute risk reductions (ARRs) in ischemic stroke relative to hypothetically having been on no antithrombotic therapy (R c ) with the following formulae:
Anticoagulants: R oac /0.33−R oac , where R oac equals the rate of ischemic stroke on a given anticoagulant, in view of the 0.67% relative risk reduction in ischemic stroke with warfarin compared with control/placebo, 1 and all non-vitamin K antagonist oral anticoagulants (NOACs) providing equivalent ischemic stroke prevention compared with warfarin in subgroup analyses of patients with previous ischemic stroke/TIA. Estimated net benefit or harm for the composite outcome of both ischemic and hemorrhagic strokes was calculated by subtracting the estimated hemorrhagic stroke rate from the estimated ARR in ischemic stroke with negative values suggesting a trend toward harm (Tables 2 and 3) .
The most significant assumptions in our estimates are (1) the RR of CMBs reported in meta-analyses, including all ischemic stroke/ TIA subtypes, are applicable to patients with ischemic stroke/TIA with AF and (2) the RRs of CMB(s) for future ischemic and hemorrhagic strokes are not altered by different antithrombotic agents. Although these assumptions are rather imperfect, they are reflective of the assumptions used during decision-making in clinical practice where definitive evidence is lacking, through application of the currently best available relevant data.
Results
We included subgroup analysis data from 5 randomized controlled trials. All subgroups reported either a CHADS 2 ≥3 in >90% of participants or a mean CHADS 2 of ≈4 (Table 1) .
Among all oral anticoagulants, including warfarin, the estimated ARR for ischemic stroke exceeded the absolute † †Estimated ARR for the studied population as compared with no antithrombotic therapy. Calculated as R asa /0.79−R asa , where R asa equals the rate of IS (given 0.21% Relative risk reduction in IS prevention in atrial fibrillation with aspirin compared with control/placebo).
Stroke
December 2017 estimated rates of hemorrhagic stroke across all CMB categories (Table 1 ). In fact, because of their greater estimated absolute rates of ischemic stroke, patients with CMBs had greater margins of benefit from anticoagulant treatment ( Table 2) . Among patients with ≥5 CMBs, the greatest margin of benefit was observed with rivaroxaban in ROCKET-AF, where the estimated absolute hemorrhagic stroke rate was 4.79% per year, whereas treatment with rivaroxaban provided an estimated 12.83% ARR relative to having been on no antithrombotic therapy, for an estimated net benefit of 8.04% for the composite of ischemic and hemorrhagic strokes. For the same ≥5 CMBs subgroup, those randomized to warfarin in the ROCKET-AF trial had an estimated 6.49% risk of hemorrhagic stroke and 12.44% ARR for ischemic stroke, for an attenuated but preserved net benefit of 5.95%. The only suggestion for net harm was estimated in patients randomized to aspirin in whom the estimated rates of hemorrhagic stroke exceeded the ARR of ischemic stroke across all the CMB subgroups ( Table 2) . Because the 1.07% per year rate of hemorrhagic stroke reported in subgroup analysis of trial participants with previous stroke and TIA allocated to aspirin in AVERROES seems higher than expected and is possibly skewed because of the small sample size within this subgroup (n=374), we performed further exploratory analyses using the original trial data in all-comers randomized to aspirin (reported hemorrhagic stroke rate, 0.30% per year; ischemic stroke rate, 3% per year; n=2791). 8 Using data from all-comers on aspirin (including participants with and without prior stroke/TIA), which as a whole are at lower risk of both ischemic and hemorrhagic strokes, there existed persistent suggestion for harm in patients with CMBs, particularly in patients with ≥5, lobar, and mixed CMBs, who had estimated annual hemorrhagic stroke rates of 4.23%, 3.15%, and 3.33% and estimated ARR in ischemic stroke of 2.15%, 1.59%, and 2.07% resulting in suggested annual net harm of 2.08%, 1.56%, and 1.26%, respectively (Table 3) .
Discussion
Our estimates support that the considerable net benefit of anticoagulant therapy in AF persists in patients with ischemic stroke/TIA with CMBs, even in the presence of strictly lobar, mixed, or ≥5 CMBs. The estimated margins of benefit continue to favor anticoagulation over aspirin therapy and NOACs over warfarin in patients with ischemic stroke/TIA with AF and CMBs on MRI.
In contrast to existing concern about anticoagulating patients with higher CMB burden, 6,13 our estimates suggest that patients with greater CMB counts may have even greater net benefit from anticoagulation because of their greater absolute risks of ischemic stroke relative to hemorrhagic stroke. Moreover, our estimated margins of benefit are rather conservative when considering that the estimated hemorrhagic stroke rates reported here are inclusive of the baseline rate of hemorrhagic stroke within these subgroups without any antithrombotic therapy. Given that previous studies have demonstrated an estimated 2-fold increased rate of hemorrhagic stroke with warfarin over no antithrombotic therapy, and the reported halving of hemorrhagic stroke rates with NOACs relative to warfarin in recent trials, 14 the contribution of NOACs to hemorrhagic stroke risk is likely a marginal one. Hence, the magnitude of benefit with NOACs in this disease population is likely even greater than that perceived on the surface from our crude estimates. Although we found certain NOACs to have greater margins of benefit relative to others, indirect comparisons of our estimates across anticoagulants should be treated cautiously because they are derived from variances in trial-specific event rates, which may reflect differences in trial populations rather than varying treatment effects.
Data on CMB prevalence in patients with AF would suggest that up to one third of participants in recent AF trials could have had CMBs at study entry, [15] [16] [17] and there have been no unfavorable treatment interactions for the outcome of stroke (ischemic/hemorrhagic) and systemic embolism or intracranial hemorrhage reported in subgroups that would be at the highest risk for CMBs, such as the elderly or patients with hypertension. 14, [18] [19] [20] [21] [22] Conversely, similar to our estimates for greater CMB counts, subgroup analyses of the AVERROES trial have reported significant greater margins of benefit with apixaban relative to aspirin with increasing age. 20 Of particular Margin calculated by subtracting estimated hemorrhagic stroke rates from the estimated absolute risk reductions for ischemic stroke reported in Table 1 . Negative values suggest a trend toward harm. CMB indicates cerebral microbleeds; and INR, international normalized ratio.
interest, rates of intracranial bleeding in patients ≥85 years of age were lower on apixaban compared with aspirin (0.5% versus 2.9% per year; hazard ratio, 0.17; 95% confidence interval, 0.01-1.02; P value for treatment effect, 0.05; P value for age interaction, 0.04). 23 Further reassurances are provided from an MRI substudy embedded within AVERROES trial, which reported similar CMB accrual during follow-up in patients with AF treated with apixaban compared with aspirin. 24 In contrast to our estimates for NOACs and warfarin, the only suggestion for harm in our estimates was with the use of aspirin, 81 mg. The greatest suggestion of harm was in patients with ≥5 CMBs taking aspirin who had considerably less ARR in ischemic stroke compared with NOACs (5.35% versus 9.59%-12.83%), without a lower hemorrhagic stroke rate. However, even within this context, for there to be a net increase in the composite of ischemic and hemorrhagic strokes, or net harm, aspirin would have to increase the baseline absolute hemorrhagic stroke rate by >5.35%, which is unlikely because the reported relative increase in hemorrhagic stroke risk with aspirin relative to placebo/control in a metaanalysis of randomized controlled trials performed by the Antithrombotic Trialist Collaboration was ≈40% (RR, 1.39; 95% confidence interval, 1.08-1.78). 25 We concede that several assumptions in our estimates limit firm conclusions. Indeed some preliminary data suggest that the risk of future ischemic and hemorrhagic strokes associated with CMBs may differ in the setting of atrial fibrillation. 26 Hemorrhagic strokes are often more clinically severe than ischemic strokes, and focusing on event rates alone may be oversimplistic. Additional limitations include combined estimates from observational studies and randomized controlled trials, as well as the lack of confidence intervals to account for random variation.
Conclusions
It is our view that current net clinical benefit estimates from the available literature suggest that the benefits of anticoagulant therapy in AF, and in particular, those of NOACs, persist in patients with ischemic stroke/TIA with CMBs, including patients with the most concerning CMB patterns on MRI. The literature and our estimates are, however, fraught with uncertainties and assumptions. Accordingly, we look forward to the completion of ongoing real-world observational studies, such as CROMIS 2 (Clinical Relevance of Microbleeds in Stroke 2; NCT02513316) 27 and HERO (Intracerebral Hemorrhage due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance; NCT02238470), to shed additional light on the questions at hand.
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